Further to the announcement issued on 12 July 2016, Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that following the resignation of Andrew Scaife as CEO the Board has appointed Chris Rigg, the Group’s CFO, to Acting CEO with immediate effect.
Since the announcement on 12 July 2016, Chris has worked closely with Andrew on a well-managed handover of responsibilities. Andrew has now formally resigned as a director of the Company.
Chris was appointed CFO on 8 March 2016 having joined Quantum as the Group's Strategic Director in November 2015. Chris has a wealth of relevant experience in growing and leading businesses across a number of sectors and industries and has held a number of senior positions, including most recently CEO of Northern Recruitment Group. Other senior roles include Managing Director of eaga plc's solar division and Head of Large Corporate Lending at Barclays in the North East.
Chris will combine the role with his duties as CFO. A search process for a new CEO has commenced and the Company will provide an update on this in due course.
John Clarke, Chairman of Quantum Pharma, commented: “The Board joins me in thanking Chris for accepting the position of Acting CEO whilst we continue our search for a permanent CEO. Chris has excellent knowledge of the Group and its operations and is well placed to drive the business forward over the coming months.”
Posted by: Quantum Webmaster on 1st August 2016